Pharmaceutical Advocacy Groups Focus on Value-of-Care Initiatives

As bio-pharmaceutical companies lose the ability to communicate externally because of increased regulatory and media scrutiny, the role of internal Advocacy groups will become more important to a company's success. These groups will tackle the emphasis on cost effectiveness of care by communicating concepts and arranging programs and partnerships that address the value of care.Since internal Advocacy groups are not known for large budget or staff numbers, more than 75 percent of Advocacy groups employ differentiated service levels to different internal customers to ensure that scarce resources are allocated to the points of greatest economic impact or leadership authority, such as value of care initiatives, according to "Advocacy Excellence: Optimizing Group Structure & Operations," primary research conducted by Best Practices, LLC.Download a complimentary white paper at http://www3.best-in-class.com/rr1125.htm that includes selected best practices drawn from quantitative and qualitative research with advocacy leaders from 11 leading biopharmaceutical companies.